Abstract:This fourth issue of Neuropsychopharmacology Reviews focuses on cognition, the ultimate function of the brain. Arguably, most, if not all, of the major neuropsychiatric disorders such as schizophrenia, depression, and anxiety are cognitive in nature. Increasingly, it is realized that symptoms such as delusions and hallucinations, as well as other motivational and emotional signs, may have important cognitive elements. These arise, for example, from aberrant learning and associative factors, impaired attributional systems, and deficient control processes that are recruited to regulate emotional outputs and inappropriate behavioral responses. In general, cognition refers to those, sometimes mysterious, covert processes that have to be inferred from behavior. Cognitive processes include seemingly miraculous products of modular processing to produce, for example, representational knowledge such as language, and mechanisms that intervene between stimulus and response, often in a ‘top-down' or ‘executive' manner to mediate and resolve competition between what are often autonomous neurocognitive systems. Deficits in such cognitive processes as working memory are now acknowledged to be important factors in their own right that determine the likelihood of rehabilitation in disorders such as schizophrenia, and this has led to recent initiatives of the National Institute of Health such as the MATRICS project on the measurement and remediation of cognitive functions for the purpose of clinical trials (Green, 2007). Moreover, the state of psychiatric genetics is helping us to realize that the accurate definition of phenotype, and the corollary identification of cognitive endophenotypes, is a vital aim in any program that seeks to understand the genetic basis of psychopathology. Great advances in cognitive neuroscience over the past two decades, aided by technological innovations in several modalities of brain imaging, as well as increased sophistication in computational theory and cognitive psychology, have inspired psychopharmacologists and biological psychiatrists alike to characterize the properties of candidate cognition-modifying compounds, beneficial or otherwise. In this Special Issue, we have tried to capture some of the excitement of this burgeoning area of research, and how it may inspire future advances in the field, with an emphasis on translational strategies. We have focused on current hot-spots of debate and potential growth areas by commissioning well-refereed reviews (often entailing novel collaborations) that either complement one another or stand apart, like beacons, to inspire new discovery. We have chosen not to re-review areas where recent authoritative pieces have removed the need (eg, the role of noradrenergic mechanisms (eg, Arnsten, 2009)). The result is a collection of 16 substantial reviews sequenced to highlight their most obvious inter-relationships. The series begins with a review by Coull et al that uniquely synthesizes neuropsychopharmacological and neuroimaging evidence from human and animal studies on timing—a fundamental and yet intangible process that permeates and underlies most cognitive functions. Kenemans and Kahkonen help us to appreciate the potential of contemporary methods in human electrophysiology, including magnetoencephalography, which have the necessary precision and temporal resolution to illuminate attentional and response preparatory processes and how they are altered by psychoactive drugs. Many such effects arise from drugs affecting monoaminergic systems and so we have covered the important advances accruing from analyses of the monoaminergic and cholinergic systems. Thus, Hasslemo and Sarter review progress in understanding the role of cholinergic systems in attentional and memory processes at a mechanistic level. Several articles then converge on the implications of remarkable advances in understanding the roles and modes of the central dopamine projections that may inspire the resolution of similar questions about the role of the 5-HT systems. Articles by Boureau and Dayan, and Cools et al both illustrate the advantages of combining new approaches in computational and imaging neuroscience to gain fresh and complementary perspectives on such classical issues of putative unitary functions and opponency of these monoaminergic systems. Rogers shows how such analyses may inform our understanding of decision-making processes in humans and Frank and Fossella introduce a pharmacogenetic perspective, again with emphasis on monoaminergic systems. Possible clinical applications of advances in understanding of cortico-limbic circuitry under neuromodulatory control are then covered by two contrasting chapters on cognition in depression. One (by Elliott et al) covers the implications of new discoveries about reward systems and emotional regulation and the other (by Pizzagalli) identifies, through meta-analysis, a possible neuroendophenotype for treatment of depression based on hyperactivity of the rostral anterior cingulate cortex, which is then interpreted in the context of other elements of this circuitry and their purported cognitive functions. The next article (by Volkow et al) provides perhaps the best evidence relating to possible cognitive enhancement, mainly through stimulant medications in the treatment of attention-deficit hyperactivity disorder (ADHD). The great interest in cognitive enhancing drugs, relevant, for example, to programs in schizophrenia, is then reviewed from the perspective of animal studies of memory and executive function (by Floresco and Jentsch) before Hardt and Nadel provide a stimulating and timely update on theoretical advances in understanding memory systems, especially for episodic memory. The last decade has seen enormous advances in revealing how glutamatergic processes affect plasticity and learning and this is represented here by a survey of the fascinating processes underlying extinction, their susceptibility to manipulation through glutamatergic drugs and the novel implications for clinical treatment of such conditions as anxiety and addiction (by Myers et al). Corlett et al illustrate another side of the NMDA receptor coin: the imaginative use of the ketamine model of psychosis in humans to understand the cognitive and neural basis of delusional phenomena. Lesh et al then review the characterization of cognitive deficits in schizophrenia from a particular theoretical position that emphasizes impairments in cognitive control processes. We look forward to the next issue of Neuropsychopharmacology Reviews with its clinical and applied themes, by reviewing a vital element of clinical trials—the neurocognitive basis of the placebo effect (by Benedetti et al). Last, but by no means least, these substantial reviews are highlighted by an extraordinarily stimulating set of ‘hot topics', which help to fill in the gaps of our inevitably incomplete coverage (and definitely enable us to say we have considered both ‘hot' and ‘cold' cognition!). It has been a privilege to edit this Special Issue and I would like to pay tribute to the efforts of the authors, referees, as well as my co-editing colleagues Peter Kalivas, Gwenn Smith, Kathryn Cunningham, and Diane Drexler.

Abstract:Event Abstract Back to Event Brain-Integrated Psychiatry: Neuroimaging-aided Comprehensive Cognitive Assessment towards informed Diagnosis and Treatment in Schizophrenia Adrian Curtin1, 2*, Junfeng Sun2, Qiangfeng Zhao2, Banu Onaral1, Jijun Wang3, Shanbao Tong2 and Hasan Ayaz1, 4, 5 1 School of Biomedical Engineering, Science and Health Systems, Drexel University, United States 2 School of Biomedical Engineering, Shanghai Jiao Tong University, China 3 Shanghai Mental Health Center (SMHC), China 4 University of Pennsylvania, Department of Family and Community Health, United States 5 Children's Hospital of Philadelphia, Division of General Pediatrics, United States A critical issue in modern psychiatry is the lack of objective biomarkers which grant insight into patient status and diagnosis. In particular, in Schizophrenia, a severe and disabling mental disorder characterized by deficits in cognitive processes, perception, and emotional responsiveness, both clinical diagnosis and status are evaluated only using behavioral measures or subjective self-reports of patients. The high degree of heterogeneity in patients with Schizophrenia presents a particular challenge to physicians as the manifest symptoms and best therapeutic approach are with high individual variability (Lehman, Lieberman, & Dixon, 2010). Treatment-resistant patients, who do not respond successfully to initial treatments, may be discouraged from attempting further strategies and jeopardize future medication adherence(Liu-Seifert, Adams, & Kinon, 2005). Therefore, there is a distinct clinical need for technologies which can be used to quickly optimize current pharmacological therapies as well as evaluate the impact of developing conjunctive approaches such as cognitive behavioral therapy and neurostimulation. Dysfunction in the prefrontal cortex is considered to be a hallmark of Schizophrenia and is associated with cognitive deficits which pre-date psychosis and manifest themselves in a broad range of domains including attention, working memory, and verbal fluency(Minzenberg, Laird, Thelen, Carter, & Glahn, 2009). Measurement of functional biomarkers in this region show great potential to form candidate biomarkers helping clinicians tailor treatments to individual patients needs based on their particular functional-cognitive profile. Prefrontal cortex activity can be effectively and routinely monitored by using Functional Near-Infrared Spectroscopy (fNIRS) which non-invasively measures cortical hemodynamic responses using near-infrared light with safe, portable and wearable sensors(Ayaz et al., 2013). Through the measurement of functional responses to a multi-domain cognitive task battery in combination with functional neuroimaging techniques such as fNIRS, a composite biomarker of clinical status can be established to inform future therapy through Brain-Integrated Psychiatry (Figure 1). In the present study, twenty-four schizophrenia patients and sixteen healthy controls were recruited to participate in a study of functional differences associated with Schizophrenia and relevant clinical correlates. Participants completed tasks from multiple cognitive domains including working memory (N-Back), speed of processing (Symbol Digit Substitution Task), verbal fluency (Verbal Fluency Task), and sustained attention (Sustained Attention Task), while functional activation in the prefrontal cortex was simultaneously monitored by fNIRS. Results from our collaborative study support fNIRS’ ability to capture neural biomarkers that can differentiate patients from healthy controls (Figure 2, Optode 3: F 1, 28 =5.09, p=0.032; Optode 13: F 1, 28 =4.418, p=0.045) and serve as estimations of patients’ clinical status (Figure 3, Opt7: rho=-0.55, p=0.022, Opt8: rho=-0.53, p=0.042). Both fNIRS biomarkers integrated measures of neural efficiency, appear to indicate different aspects of patient status. These markers offer candidate markers for diagnosis, classification, and monitoring of Schizophrenia treatment response. Together, this project aims to combine non-invasive neuroimaging methodologies with behavioral cognitive metrics to give physicians an objective clinical evaluation of pharmacotherapy methods. Figure 1: A template for Brain-integrated Psychiatry during the intervention in Schizophrenia using fNIRS-guided Pharmacotherapy. Figure 2: Absence of lateral-Prefrontal Cortex activation during Speed of Processing task differentiates patients with Schizophrenia from Healthy controls. (A) Mean temporal changes in [Oxy] for Optode 13 during Symbol-Digit Substitution Task (B) Parametric plot of mean [Oxy] differences between groups in dorsolateral-Prefrontal Cortex; (C) Mean temporal changes in [Oxy] for Optode 3 during Symbol-Digit Substitution Task Figure 3: Left-Prefrontal Cortex Involvement in 0-Back negatively correlated with PANSS- General (A) Parametric plot of correlation of mean [Oxy] changes during 0-Back performance with PANSS-General scores (Spearman’s Rho) (B) Correlation of changes in mean [Oxy] in Optode 8 with PANSS- General Scores Figure 1 Figure 2 Figure 3 References Ayaz, H., Onaral, B., Izzetoglu, K., Shewokis, P. A., McKendrick, R., & Parasuraman, R. (2013). Continuous monitoring of brain dynamics with functional near infrared spectroscopy as a tool for neuroergonomic research: empirical examples and a technological development. Frontiers in Human Neuroscience, 7(DEC), 871. https://doi.org/10.3389/fnhum.2013.00871 Lehman, A., Lieberman, J., & Dixon, L. (2010). Practice Guideline for Treatment of Patients With Schizophrenia Second Edition. American Journal of Psychiatry. https://doi.org/10.1176/appi.books.9780890423363.45859 Liu-Seifert, H., Adams, D. H., & Kinon, B. J. (2005). Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine, 3, 21. https://doi.org/10.1186/1741-7015-3-21 Minzenberg, M. J., Laird, A. R., Thelen, S., Carter, C. S., & Glahn, D. C. (2009). Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Archives of General Psychiatry, 66(8), 811–22. https://doi.org/10.1001/archgenpsychiatry.2009.91 Keywords: fNIRS, Prefrontal Cortex, Schizophrenia, Cognition, Psychiatry Conference: 2nd International Neuroergonomics Conference, Philadelphia, PA, United States, 27 Jun - 29 Jun, 2018. Presentation Type: Oral Presentation Topic: Neuroergonomics Citation: Curtin A, Sun J, Zhao Q, Onaral B, Wang J, Tong S and Ayaz H (2019). Brain-Integrated Psychiatry: Neuroimaging-aided Comprehensive Cognitive Assessment towards informed Diagnosis and Treatment in Schizophrenia. Conference Abstract: 2nd International Neuroergonomics Conference. doi: 10.3389/conf.fnhum.2018.227.00081 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 05 Apr 2018; Published Online: 27 Sep 2019. * Correspondence: Mr. Adrian Curtin, School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, United States, abc48@drexel.edu Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Adrian Curtin Junfeng Sun Qiangfeng Zhao Banu Onaral Jijun Wang Shanbao Tong Hasan Ayaz Google Adrian Curtin Junfeng Sun Qiangfeng Zhao Banu Onaral Jijun Wang Shanbao Tong Hasan Ayaz Google Scholar Adrian Curtin Junfeng Sun Qiangfeng Zhao Banu Onaral Jijun Wang Shanbao Tong Hasan Ayaz PubMed Adrian Curtin Junfeng Sun Qiangfeng Zhao Banu Onaral Jijun Wang Shanbao Tong Hasan Ayaz Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.

Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: an Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative

Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders

CNTRICS Final Task Selection: Executive Control

Measuring the Construct of Executive Control in Schizophrenia: Defining and Validating Translational Animal Paradigms for Discovery Research

CNTRICS Final Animal Model Task Selection: Control of Attention.

Cognition: the Ultimate Brain Function

Distinguishing Separable Domains of Cognition in Human and Animal Studies: What Separations Are Optimal for Targeting Interventions? A Summary of Recommendations from Breakout Group 2 at the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference.

Standardizing Attention Process Training-III for a Multisite Clinical Trial of Neuromodulation

Assessing Cognitive Function in Clinical Trials of Schizophrenia

Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection

National Institute of Mental Health Support for Cognitive Treatment Development in Schizophrenia: A Narrative Review

Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities

Neurocognitive therapeutics: from concept to application in the treatment of negative attention bias

Translating Cognition from Animals to Humans

Brain-Integrated Psychiatry: Neuroimaging-aided Comprehensive Cognitive Assessment Towards Informed Diagnosis and Treatment in Schizophrenia

T188. THE CLINICAL SCIENCE OF TRANSCRANIAL DIRECT CURRENT STIMULATION STUDIES IN SCHIZOPHRENIA: SYSTEMATIC REVIEW AND META-ANALYSIS

Translational Neuroscience: Toward New Therapies

Utilizing a transdiagnostic neuroscience-informed approach to differentiate the components of a complex clinical presentation: A case report

Improving Methodological Standards in Behavioral Interventions for Cognitive Enhancement

Efficacy of social cognition and interaction training in outpatients with schizophrenia spectrum disorders: randomized controlled trial